Close

Summary of the Data:

The Georgia Pediatric Antibiogram combines antibiogram data from the five children’s hospitals in Georgia from 2014 through the current antibiogram data.

Antibiotic susceptibility data for the following bacteria are included:

  • Staphylococcus aureus (methicillin resistant and susceptible isolates are reported separately)

  • Enterococcus faecalis

  • Streptococcus pneumoniae

  • Escherichia coli

  • Enterobacter cloacae complex

  • Klebsiella pneumoniae

  • Pseudomonas aeruginosa

The antibiogram follows the Clinical Laboratory Standards Institute (CLSI) guideline recommending that a single isolate per patient per year is used as the key data element so that rates can be compared from one institution to another, irrespective of geographic location.

Keep in mind that this antibiogram in no way substitutes for culturing and assessing susceptibility profiles for therapy or for monitoring changes in resistance over time for any individual patient.


Pediatric Antibiogram Data Visualization Tool

Important Considerations for Interpreting the Antibiogram Data:

  • These data do not constitute medical advice and should not be relied upon as a substitute for independent medical judgment.

  • Antibiotic susceptibility data are based on isolates obtained from cultures obtained from pediatric patients evaluated in the hospital emergency departments and inpatient units of the participating children’s hospitals. As such, these data may show slightly lower susceptibility rates than may be present in the surrounding community.

  • Nitrofurantoin is only used for treating uncomplicated urinary tract infections.

  • Escherichia coli susceptibility for Cefazolin (urine) is determined using cefazolin uncomplicated urinary tract infection (UTI) breakpoints, whereas systemic breakpoints are listed as Cefazolin (non-urine or not specified).

  • Susceptibility data for Pseudomonas aeruginosa do not include isolates recovered from cystic fibrosis patients from Atlanta, Augusta, Columbus and Macon.

  • For Streptococcus pneumoniae, note that the aminopenicillins, including amoxicillin and ampicillin, can be inferred from the amoxicillin/clavulanate results.

  • Clindamycin results for S. pneumoniae have NOT been adjusted to account for the presence of inducible clindamycin resistance for isolates from Atlanta and Macon.

  • Oxacillin susceptible staphylococci should be considered susceptible to penicillinase-stable penicillins (e.g., nafcillin, oxacillin), beta-lactam/beta-lactamase inhibitor combinations (e.g., amoxicillin/clavulanate), cephalosporins and carbapenems.

  • Oxacillin resistant staphylococci should be considered resistant to all penicillins, cephalosporins, carbapenems, and beta-lactam/beta-lactamase inhibitor combinations (e.g., amoxicillin/clavulanate).

  • For serious enterococcal infections, combination therapy using ampicillin or vancomycin plus gentamicin, or streptomycin is strongly recommended.